Key result
Digoxin-like immunoreactive substance was detected in only 23% of patients not receiving digoxin by two of four immunoassay kits, indicating less interference than previously reported.
Why the study?
Does digoxin-like immunoreactive substance (DLIS) cause significant interference in commercial digoxin immunoassays in patients with renal impairment?
Population
50 patients with elevated serum creatinine, including 10 receiving digoxin therapeutically and 40 not…
Design
Cross-sectional
Authors
Loading...
DLIS interference may be less prevalent and kit-specific in renal impairment than previously thought; challenges earlier estimates while leaving clinical monitoring implications open.
Observational (n=50)
Does digoxin-like immunoreactive substance (DLIS) cause significant interference in commercial digoxin immunoassays in patients with renal impairment?
Absolute Event Rate: 23% vs 0%
The extent of interference by digoxin-like immunoreactive substance in digoxin immunoassays in patients with renal impairment is lower than previously reported and varies by assay kit.
Greenway et al. (2008) conducted an observational in Renal impairment (n=50). Digoxin immunoassay kits was evaluated on Detection of digoxin-like immunoreactive substance (DLIS). Digoxin-like immunoreactive substance was detected in only 23% of patients not receiving digoxin by two of four immunoassay kits, indicating less interference than previously reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: